Lindane-containing lice treatments will undergo relabeling to warn of overuse, discuss alternatives.
LINDANE PRODUCT LABELS WILL BE REVISED TO RECOMMEND SECOND-LINE USE ONLY in the treatment of lice. FDA is recommending lindane (gamma benzene hexachloride) use only for patients who have failed to respond to, or are intolerant of, other approved lice and scabies therapies that do not contain lindane. The FDA-prompted changes are in response to claims that lindane, an insecticide used in prescription-only pediculicides, might cause neurological damage in children.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth